Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma

[1]  G. Plitas,et al.  Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma , 2021, npj Breast Cancer.

[2]  G. Plitas,et al.  Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype , 2021, Annals of Surgical Oncology.

[3]  I. Chen,et al.  Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components , 2020, Virchows Archiv.

[4]  G. Viale,et al.  Metaplastic breast cancer: Prognostic and therapeutic considerations , 2020, Journal of surgical oncology.

[5]  E. Brogi,et al.  Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy , 2020, Annals of Surgical Oncology.

[6]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[7]  Metaplastic Carcinoma , 2020, Definitions.

[8]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Visscher,et al.  Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy , 2019, Breast cancer research and treatment.

[10]  D. Dabbs,et al.  Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy , 2019, Modern Pathology.

[11]  A. Vincent-Salomon,et al.  High rate of PIK3CA mutations but no TP53 mutations in low‐grade adenosquamous carcinoma of the breast , 2018, Histopathology.

[12]  P. Fasching,et al.  Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial , 2018, Clinical Cancer Research.

[13]  T. Hyslop,et al.  Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database , 2018, Annals of Surgical Oncology.

[14]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[16]  L. Miller,et al.  Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. , 2018, The oncologist.

[17]  T. Khoury,et al.  Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple‐negative Breast Cancer: A Study From a Single Institution and Review of Literature , 2017, Clinical breast cancer.

[18]  I. Ellis,et al.  Immunoprofile of metaplastic carcinomas of the breast , 2017, Histopathology.

[19]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[20]  O. Mariani,et al.  The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas , 2017, Clinical Cancer Research.

[21]  Mei Liu,et al.  Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Adams,et al.  Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. , 2016, JAMA oncology.

[23]  E. Rakha,et al.  Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. , 2016, The British journal of radiology.

[24]  G. Plitas,et al.  How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study , 2016, Annals of Surgical Oncology.

[25]  P. Argani,et al.  A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma. , 2016, American journal of clinical pathology.

[26]  L. Esserman,et al.  Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group , 2015, Modern Pathology.

[27]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[28]  B. Clark,et al.  Low-grade fibromatosis-like spindle cell carcinoma of the breast. , 2015, Archives of pathology & laboratory medicine.

[29]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  K. Hunt,et al.  Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial , 2014, Annals of surgery.

[31]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[32]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[33]  T. Shibata,et al.  Metaplastic carcinoma of breast , 2014 .

[34]  S. Bhosale,et al.  Squamous cell carcinoma of the breast , 2013, The American journal of case reports.

[35]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Lee,et al.  The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients , 2011, Breast Cancer Research and Treatment.

[37]  Byung-Ho Nam,et al.  Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer , 2010, Breast Cancer Research and Treatment.

[38]  K. Bland,et al.  Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base , 2006, Annals of Surgical Oncology.

[39]  S. Lakhani,et al.  Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.

[40]  N. Sneige,et al.  Metaplastic Sarcomatoid Carcinoma of the Breast With Absent or Minimal Overt Invasive Carcinomatous Component: A Misnomer , 2005, The American journal of surgical pathology.

[41]  G. Hortobagyi,et al.  Squamous cell carcinoma of the breast. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Gown,et al.  Low-Grade (Fibromatosis-Like) Spindle Cell Carcinoma of the Breast , 2001, The American journal of surgical pathology.

[43]  J. Simpson,et al.  Metaplastic breast tumors with a dominant fibromatosis‐like phenotype have a high risk of local recurrence , 1999, Cancer.

[44]  M. Cranor,et al.  Low-Grade Adenosquamous Carcinoma of the Breast: A Clinocopathologic Study of 32 Cases with Ultrastructural Analysis , 1993, The American journal of surgical pathology.

[45]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[46]  R. Nelson,et al.  Survival Outcomes of Metaplastic Breast Cancer Patients: Results from a US Population-based Analysis , 2014, Annals of Surgical Oncology.

[47]  V. Valero,et al.  Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers , 2011, Breast Cancer Research and Treatment.

[48]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.